Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.54 |
| ▸ | AHCY | P23526 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29318369 | 1.00 | YTHDC1 (0.59) | YTHDC1ALDH1A1LMNAALBMAPK1 | |
| Phenol SCHEMBL27699602 | 0.92 | ABL1 (0.52) | YTHDC1ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL18410858 | 0.89 | YTHDC1 (0.60) | YTHDC1ADORA3AHCY | |
| SCHEMBL2036287 | 0.88 | ALDH1A1 (0.55) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL20419240 | 0.88 | ALDH1A1 (0.57) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL22524099 | 0.88 | YTHDC1 (0.59) | YTHDC1ADORA3AHCY | |
| SCHEMBL23982425 | 0.87 | ABL1 (0.66) | ABL1RIN1 | |
| SCHEMBL21138875 | 0.86 | YTHDC1 (0.56) | YTHDC1ADORA3AHCY | |
| SCHEMBL21082466 | 0.86 | YTHDC1 (0.56) | YTHDC1ADORA3AHCY | |
| SCHEMBL22452225 | 0.85 | TSHR (0.64) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616447-B2 | Method and system for spectral analysis and determination of a marker making it possible to ensure the safety of therapeutic ultrasound interventions | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2026-05-05 | — | — | US | claimed |
| CN-118570631-A | Small sample hyperspectral image classification method based on contrast learning and Markov distance domain adaptation | 安徽师范大学 | 2024-08-30 | — | — | CN | claimed |
| CN-117964910-A | Preparation method and application of flame retardant based on metal organic framework material and MXene | 中国安全生产科学研究院 | 2024-05-03 | — | — | CN | claimed |
| EP-3870060-B1 | SYSTEM FOR SPECTRAL ANALYSIS AND DETERMINATION OF A MARKER MAKING IT POSSIBLE TO ENSURE THE SAFETY OF THERAPEUTIC ULTRASOUND INTERVENTIONS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-04-17 | — | — | EP | claimed |
| US-20240060037-A1 | MODIFIED ORGANISMS FOR ETHYLENE, ETHANE, AND METHANE BIOGENESIS AND METHODS FOR USE THEREOF | OHIO STATE INNOVATION FOUNDATION | 2024-02-22 | — | — | US | claimed |
| WO-2022204489-A1 | MODIFIED ORGANISMS FOR ETHYLENE, ETHANE, AND METHANE BIOGENESIS AND METHODS FOR USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2022-09-29 | — | — | WO | claimed |
| CN-102753526-B | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIV GEORGIA | 2014-11-26 | — | — | CN | claimed |
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | claimed |
| EP-2509949-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | University Of Georgia Research Foundation, Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071849-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | claimed |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | US | claimed |
| EP-2046328-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| WO-2008010953-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-12616447-B2 | Method and system for spectral analysis and determination of a marker making it possible to ensure the safety of therapeutic ultrasound interventions | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2026-05-05 | — | — | US | disclosed |
| WO-2004003185-A2 | PLANT DEOXYRIBONUCLEOSIDE KINASE ENZYMES AND THEIR USE | KNECHT WOLFGANG (SE) | 2004-01-08 | — | — | WO | disclosed |
| WO-1991000867-A1 | 5'-DIPHOSPHOHEXOSE NUCLEOSIDE PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | TKT, DHFR, DTYMK | YTHDC1 2649/4885ALDH1A1 1645/4885LMNA 3285/4885 |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | PAICS, DUT, AADAC | YTHDC1 1355/4885ALDH1A1 2717/4885LMNA 3895/4885 |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | YTHDC1 258/4885ALDH1A1 1106/4885LMNA 1899/4885 |
| US-12616447-B2 | Method and system for spectral analysis and determination of a marker making it possible to ensure the safety of therapeutic ultrasound interventions | VEGFA, CUTA, MB | YTHDC1 982/4885ALDH1A1 4697/4885LMNA 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.